Endocrinology News and Research

Latest Endocrinology News and Research

People in developing countries spend 90% of all medical expenditures for diabetes care

Type 2 diabetes is often seen as a condition affecting older, unproductive adults in wealthy countries. However, the reality is that 70% of people with diabetes now live in low and middle-income countries and the economic impact of diabetes is much greater in poorer countries.

22 Oct 2009

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.

22 Oct 2009

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.

22 Oct 2009

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that The Children's Hospital of Philadelphia (CHOP), one of the leading pediatric hospitals and research facilities in the world, has implemented the InforSense-based Translational Research Solution to advance the understanding of complex genetic disease.

22 Oct 2009

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

Halozyme Therapeutics, Inc. and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze™ technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation with Roche’s anticancer biologic, Herceptin (trastuzumab).

22 Oct 2009

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

OSI Pharmaceuticals, Inc. announced today its financial results for the Company’s third quarter ended September 30, 2009. The Company reported total revenues from continuing operations of $111 million for the third quarter of 2009 compared to revenues of $95 million for the third quarter of 2008, an 18% increase over the prior year period.

22 Oct 2009

New findings from ADVANCE clinical trial presented

New analyses of the largest-ever clinical trial of patients with type 2 diabetes show that the combination of blood pressure lowering treatment and intensive glucose (blood sugar) control improved patients' vascular condition and resulted in a significant 18 percent reduction in the risk of death from all causes.

22 Oct 2009

Exposure to stress hormones and chemicals while in the womb can affect male fertility

Exposure to a combination of excess stress hormones and chemicals while in the womb could affect a man's fertility in later life, a study suggests.

22 Oct 2009

InHealth awards Southern California, Northwestern and Stanford Universities $1.4M as research grants

The Institute for Health Technology Studies (InHealth) has awarded three new research grants totaling more than $1.4 million to investigators at the University of Southern California, Northwestern University, and Stanford University. The funding will support three separate studies that will examine the social and economic impact of therapeutic medical devices, as well as the device innovation process.

22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

AAAS and partners to launch online social-networking sites for scientists

To help scientists and science trainees who hope to translate laboratory research into clinical medicine and to help minority scientists navigate their career paths, AAAS, Science Careers, and Science are launching a pair of online social-networking sites.

22 Oct 2009

Lake Health opens TriPoint Medical Center in Concord Township

Lake Health, formerly Lake Hospital System, today is celebrating the grand opening of its $155 million TriPoint Medical Center in Concord Township. A state-of-the-art digital hospital, TriPoint Medical Center is redefining the health care experience for patients, families and the community.

22 Oct 2009

New diabetes algorithm released by AACE for the management of type 2 diabetes

A new, first-of-its-kind diabetes algorithm created to help achieve glycemic (blood sugar) control in type 2 patients was published online today in the September/October edition of Endocrine Practice.

22 Oct 2009

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

Case Western Reserve University (CWRU) School of Medicine proudly announces the establishment of the CWRU Prevention Research Center for Healthy Neighborhoods (PRCHN), a collaborative research center to address common health issues faced in disadvantaged urban neighborhoods in and around Greater Cleveland.

22 Oct 2009

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

Beth Israel Deaconess Medical Center and Navigenics, Inc., a leading personal genomics company, today announced a collaboration to make personalized genomics available to doctors in training.

21 Oct 2009

New results from ADVANCE provide important insights to reduce diabetes complications

New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.

21 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

V8 100% vegetable juice aids in weight loss and lowers blood pressure

Decades of studies have documented the link between eating a diet rich in vegetables and multiple health benefits, yet nearly eight out of 10 people worldwide fall short of the daily recommendation.

21 Oct 2009

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).

21 Oct 2009

No significant differences in pregnancy outcomes with different progesterone formulations

A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

21 Oct 2009

Endocrinology News and Research

Latest Endocrinology News and Research

People in developing countries spend 90% of all medical expenditures for diabetes care

Dose optimization data from Tolerx's Phase 2 clinical study of otelixizumab

VeriChip collaborates with DRI for further development of the glucose-sensing RFID microchip

CHOP implements InforSense-based Translational Research Solution to study complex genetic disease

Halozyme Therapeutics commences patient dosing in Phase 3 Enhanze trial with Herceptin

OSI Pharmaceuticals reports total revenues of $111 million for the third quarter of 2009

New findings from ADVANCE clinical trial presented

Exposure to stress hormones and chemicals while in the womb can affect male fertility

InHealth awards Southern California, Northwestern and Stanford Universities $1.4M as research grants

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

AAAS and partners to launch online social-networking sites for scientists

Lake Health opens TriPoint Medical Center in Concord Township

New diabetes algorithm released by AACE for the management of type 2 diabetes

CWRU establishes collaborative research center to address common health issues in urban neighborhoods

Beth Israel Deaconess Medical Center collaborates with Navigenics to make personalized genomics available to doctors in training

New results from ADVANCE provide important insights to reduce diabetes complications

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

V8 100% vegetable juice aids in weight loss and lowers blood pressure

New public health tool to identify all Tier 1 candidates for H1N1 vaccination

No significant differences in pregnancy outcomes with different progesterone formulations

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Endocrinology News and Research

Latest Endocrinology News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in